Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 616 AL 630

IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Sköldunger A, Raket LL, Stellick CB, Spackman E, Hlávka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Brück C, Anderson R, Pemberton-Ross P, Urbich M, Jönsson L.

Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006. Epub 2024 Oct 8.

Juxtacortical Lesion Precedes Lobar Microbleed During Anti-amyloid β Immunotherapy

Shindo A, Hirata Y, Tomimoto H.

Intern Med. 2025 Nov 15;64(22):3284-3286. doi: 10.2169/internalmedicine.5198-24. Epub 2025 May 15.

Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable

Farrar G, Weber CJ, Rabinovici GD.

J Prev Alzheimers Dis. 2025 Jan;12(1):100008. doi: 10.1016/j.tjpad.2024.100008. Epub 2025 Jan 1.

Utility, Costs and Cost-Utility of Amyloid-PET in the Diagnostic Process of Memory Clinic Patients: A Trial-Based Economic Evaluation From AMYPAD-DPMS

van Maurik IS, Altomare D, Collij LE, Caprioglio C, Moro C, Garibotto V, Demonet JF, Scheltens P, Farrer G, Gismondi R, Stephens AW, Gispert JD, Molinuevo JL, Grau-Rivera O, Edison P, Walker Z, Jessen F, Dzrezga A, Zeyen P, Payoux P, Saint-Aubert L, Delrieu J, Nordberg A, Barkhof F, Frisoni GB, Berkhof J.

Eur J Neurol. 2025 Jun;32(6):e70197. doi: 10.1111/ene.70197.

Efficacy and Safety of Exogenous Ketones in People with Mild Neurocognitive Disorder and Alzheimer's Disease: A Systematic Literature Review

Krolak-Salmon P, Swerdlow RH, Mastain T, Dive-Pouletty C, Pooley N, Kisomi M.

Nutr Rev. 2025 Mar 1;83(3):e1034-e1048. doi: 10.1093/nutrit/nuae098.

Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases

Zavarella M, Cecchetti G, Rugarli G, Ghirelli A, Bottale I, Orlandi F, Spinelli EG, Santangelo R, Caso F, Calloni SF, Vezzulli PQ, Falini A, Magnani G, Agosta F, Filippi M.

J Neurol. 2025 Jan 24;272(2):168. doi: 10.1007/s00415-025-12910-x.

Effectiveness of probiotic supplements on cognitive function in mild cognitive impairment and Alzheimer's disease: A meta-analysis of randomized controlled trials

Peng TR, Lin HH, Tseng TL, Wu TW.

Gen Hosp Psychiatry. 2025 Nov-Dec;97:284-293. doi: 10.1016/j.genhosppsych.2025.11.004. Epub 2025 Nov 11.

Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches

Bereczki E, Mangialasche F, Barbera M, Padilla P, Hara Y, Fillit H, Solomon A, Kivipelto M.

J Prev Alzheimers Dis. 2025 Dec;12(10):100367. doi: 10.1016/j.tjpad.2025.100367. Epub 2025 Oct 27.

Structural and metabolic topological alterations associated with butylphthalide treatment in mild cognitive impairment: Data from a randomized, double-blind, placebo-controlled trial

Han X, Gong S, Gong J, Wang P, Li R, Chen R, Xu C, Sun W, Li S, Chen Y, Yang Y, Luan H, Wen B, Guo J, Lv S, Wei C.

Psychiatry Clin Neurosci. 2025 Jun;79(6):336-343. doi: 10.1111/pcn.13812. Epub 2025 Mar 31.

The Biological Intersection Between Chemotherapy-Related Cognitive Impairment and Alzheimer Disease

Torre M, Zanella CA, Feany MB.

Am J Pathol. 2025 Nov;195(11):2088-2101. doi: 10.1016/j.ajpath.2024.12.013. Epub 2025 Jan 23.

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K.

J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1.

Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis

Jeong SY, Suh CH, Lim JS, Shim WH, Heo H, Choi Y, Kim HS, Kim SJ, Lee JH.

Neurology. 2025 Apr 22;104(8):e213483. doi: 10.1212/WNL.0000000000213483. Epub 2025 Mar 19.

Efficacy of Add-On Agomelatine on Agitation, Aggression, and Neuroprotection in Alzheimer's Disease: A Randomized, Blinded, Controlled Trial

Kargar A, Fetratjoo DH, Moattar R, Tarki A, Golsokhan A, Pouyan N, Amjadi-Goojgi Z, Mostafaei H, Kakeri F, Zendehbad AS, Lima BS, Esmaily H, Noroozian M.

Am J Geriatr Psychiatry. 2025 Aug;33(8):819-834. doi: 10.1016/j.jagp.2025.03.001. Epub 2025 Mar 20.

Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial

Squitti R, Benussi A, Fostinelli S, Geviti A, Rivolta J, Ventriglia M, Micera A, Rongioletti M, Ghidoni R, Santilli M, Granzotto A, Albanese A, Binetti G, Sensi SL, Borroni B.

Biomolecules. 2025 Sep 1;15(9):1268. doi: 10.3390/biom15091268.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias